DLL3 bi-epitope compound nanobody CAR T cells

DLL3 bi-epitope compound nanobody CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed for the treatment of Delta-like ligand 3 (DLL3)-expressing malignancies, such as small cell lung cancer (SCLC) and high-grade neuroendocrine tumors. Developed using a proprietary "compound CAR" (cCAR) architecture, this construct features two distinct nanobody-derived (VHH) binding domains that target separate epitopes on the DLL3 protein. This dual-targeting strategy is intended to mitigate tumor escape caused by antigen loss or mutation. To further enhance therapeutic potency and overcome the immunosuppressive tumor microenvironment, the T cells are "armored" with Interleukin-18 (IL-18), which promotes T-cell survival, expansion, and pro-inflammatory activity. Preclinical data presented at AACR 2026 demonstrated that these armored bi-epitope cCAR T cells exhibit potent, specific cytotoxicity against DLL3-positive tumor cells in vitro and significant anti-tumor efficacy in xenograft mouse models.

Other names

armored DLL3 bi-epitope compound nanobody CAR T cellsDLL3 bi-epitope cCAR T cellsDLL-3 bi-epitope cCAR T cellsDLL 3 bi-epitope cCAR T cells